Context Navigation

← Previous Revision
Latest Revision
Next Revision →
Normal
Revision Log

WV-DIALOG-0247.txt@ 1727

Last change on this file since 1727 was 604, checked in by George Lilly, 15 years ago
Internationalization
File size: 13.0 KB

Rev	Line
[604]	1	English French Notes Complete/Exclude
	2	25. GLEASON'S SCORE FOR BIOPSY, LOCAL RESECTION, OR SIMPLE PROSTATECTOMY
	3	26. GLEASON'S SCORE FOR RADICAL PROSTATECTOMY
	4	18. BEHAVIOR CODE (ICD-O-2)
	5	10. CLASS OF CASE................:
	6	11. SYMPTOMS PRESENT AT INITIAL DIAGNOSIS:
	7	659 LOWER BACK PAIN..............
	8	660 TROUBLE URINATING............
	9	12. INITIAL METHOD OF DIAGNOSIS:
	10	661 CLINICAL DX WITH BONE LESION.
	11	662 CLINICAL DX BY RECTAL EXAM...
	12	664 DIGITAL TRANSRECTAL BIOPSY...
	13	665 INCIDENTAL FINDING IN TURP FOR BENIGN DISEASE...........
	14	666 NEEDLE BIOPSY, NOS...........
	15	667 PERINEAL BIOPSY..............
	16	669 TRUS GUIDED BIOPSY...........
	17	13. DIAGNOSTIC EVALUATION:
	18	671 BONE MARROW ASPIRATION.......
	19	672 BONE SCAN....................
	20	675 CT SCAN OF ABDOMEN...........
	21	676 CT SCAN OF PELVIS............
	22	679 PELVIC LYMPH NODE DISSECTION.
	23	683 ULTRASOUND OF ABDOMEN........
	24	684 14. RESULTS OF MOST RECENT PRE- TREATMENT PSA TEST...........
	25	16. PRIMARY SITE (ICD-O-2).......: C61.9
	26	18. BEHAVIOR CODE (ICD-O-2)......:
	27	141 20. BIOSPY PROCEDURE.............
	28	21. GUIDANCE OF BIOPSY TO PRIMARY: Not guided, no biopsy
	29	22. BIOPSY APPROACH FOR PRIMARY..: No biopsy
	30	21. GUIDANCE OF BIOPSY TO PRIMARY: Unknown/death cert only
	31	22. BIOPSY APPROACH FOR PRIMARY..: Unknown/death cert only
	32	142 21. GUIDANCE OF BIOSPY TO PRIMARY
	33	145 22. BIOSPY APPROACH FOR PRIMARY..
	34	146 23. BIOSPY OF OTHER THAN PRIMARY.
	35	26 24. DIAGNOSTIC CONFIRMATION......
	36	25. GLEASON'S SCORE FOR BIOPSY, LOCAL RESECTION, OR SIMPLE PROSTATECTOMY:
	37	Surgery codes not 02 through 40
	38	GLEASON SCORE................: 99 Unknown, not reported, or NA
	39	GLEASON SCORE................:
	40	623 GLEASON SCORE................
	41	26. GLEASON'S SCORE FOR RADICAL PROSTATECTOMY:
	42	Surgery codes not 50 through 70
	43	623.3 GLEASON SCORE................
	44	27. SIZE OF TUMOR (mm)
	45	28. REGIONAL NODES EXAMINED
	46	29. REGIONAL NODES POSITIVE
	47	30. AJCC CLINICAL STAGE (cTNM)
	48	31. AJCC PATHOLOGIC STAGE (pTNM)
	49	32. STAGED BY
	50	TABLE III - EXTENT AND STAGE OF DISEASE
	51	29 27. SIZE OF TUMOR (mm).....
	52	33 28. REGIONAL NODES EXAMINED
	53	32 29. REGIONAL NODES POSITIVE
	54	30. AJCC CLINICAL STAGE (cTNM):
	55	31. AJCC PATHOLOGIC STAGE (pTNM):
	56	32. STAGED BY:
	57	19 CLINICAL STAGE.........
	58	89 PATHOLOGIC STAGE.......
	59	33. DATE OF FIRST COURSE TREATMENT.:
	60	685 34. EXPECTED MGT/WATCHFUL WAITING..
	61	35. DATE OF NON CA-DIRECTED SURGERY:
	62	36. NON CANCER-DIRECTED SURGERY....:
	63	37. DATE OF CANCER-DIRECTED SURGERY:
	64	38. LENGTH OF STAY AFTER SURGERY...: 88 NA
	65	38. LENGTH OF STAY AFTER SURGERY...: 99 Unknown
	66	686 38. LENGTH OF STAY AFTER SURGERY...
	67	39. SURGICAL APPROACH..............:
	68	40. TYPE OF CANCER-DIRECTED SURGERY:
	69	41. SURGICAL MARGINS...............:
	70	42. SCOPE OF LYMPH NODE SURGERY....:
	71	43. TYPE OF LYMPH NODE SURGERY:
	72	44. SURGERY OF OTHER REGIONAL SITE(S), DISTANT SITE(S),
	73	OR DISTANT LYMPH NODE(S).......:
	74	45. NUMBER OF LYMPH NODES REMOVED..:
	75	47. COMPLICATIONS FOLLOWING SURGICAL FIRST COURSE OF TREATMENT:
	76	PERMANENT RECTAL INJURY........: NA, no surgery
	77	THROMBOEMBOLISM................: NA, no surgery
	78	URETHRAL STRICTURE.............: NA, no surgery
	79	48. POSTOPERATIVE DEATH W/I 30 DAYS: NA, no surgery
	80	PERMANENT RECTAL INJURY........: Unknown
	81	URETHRAL STRICTURE.............: Unknown
	82	48. POSTOPERATIVE DEATH W/I 30 DAYS: Unknown
	83	689 PERMANENT RECTAL INJURY........
	84	691 URETHRAL STRICTURE.............
	85	441 48. POSTOPERATIVE DEATH W/I 3O DAYS
	86	49. DATE RADIATION STARTED.........:
	87	50. RADIATION THERAPY..............:
	88	51. RADIATION FACILITY.............:
	89	52. INTERSTITIAL RADIATION/BRACHYTHERAPY ADMINISTERED:
	90	OTHER INTERSTITIAL, NOS........:
	91	53. ROUTE OF INTERSTITIAL RADIATION/
	92	BRACHYTHERAPY ADMINISTERED.....:
	93	54. EXTERNAL RADIATION ADMINISTERED:
	94	DISTANT METASTATIC SITES.......:
	95	PROSTATE & PELVIC NODES........:
	96	PROSTATE & PARA-AORTIC NODES...:
	97	PROSTATE REGION ONLY...........:
	98	OTHER EXTERNAL SITES, NOS......:
	99	55. TYPE OF EXTERNAL RADIATION
	100	56. TOTAL EXTERNAL RAD DOSE (cGy) INCLUDING BOOST:
	101	PELVIC NODES...................:
	102	PARA-AORTIC NODES..............:
	103	57. COMPLICATIONS FOLLOWING RADIATION FIRST COURSE OF TREATMENT:
	104	ACUTE GASTROINTESTINAL.........:
	105	ACUTE GASTROURINARY............:
	106	CHRONIC REQUIRING SURGERY OR
	107	PROLONGED HOSPITALIZATION......:
	108	URETHRAL OR BLADDER............:
	109	692 51. RADIATION FACILITY.............
	110	631 OTHER INTERSTITIAL, NOS........
	111	693 53. ROUTE OF INTERSTITIAL RADIATION/ BRACHYTHERAPY ADMINISTERED.....
	112	636 DISTANT METASTATIC SITES.......
	113	634 PROSTATE & PELVIC NODES........
	114	635 PROSTATE & PARA-AORTIC NODES...
	115	633 PROSTATE REGION ONLY...........
	116	637 OTHER EXTERNAL SITES, NOS......
	117	694 55. TYPE OF EXTERNAL RADIATION ADMINISTRATION.................
	118	639 PELVIC NODES...................
	119	640 PARA-AORTIC NODES..............
	120	695 ACUTE GASTROINTESTINAL.........
	121	696 ACUTE GASTROURINARY............
	122	698 CHRONIC REQUIRING SURGERY OR PROLONGED HOSPITALIZATION......
	123	699 URETHRAL OR BLADDER............
	124	58. DATE OF ORCHIECTOMY............: 00/00/0000
	125	699.1 58. DATE OF ORCHIECTOMY............
	126	59. DATE EXOGENOUS HT BEGAN........:
	127	60. HORMONE THERAPY................:
	128	61. EXOGENOUS HORMONE AGENTS ADMINISTERED:
	129	LUTEINIZING HORMONES...........:
	130	PROGESTATIONAL AGENTS..........:
	131	646 LUTEINIZING HORMONES...........
	132	645 PROGESTATIONAL AGENTS..........
	133	62. DATE CHEMOTHERAPY STARTED......:
	134	64. DATE OF FIRST RECURRENCE
	135	65. TYPE OF FIRST RECURRENCE
	136	64. TYPE OF FIRST RECURRENCE
	137	65. DATE OF FIRST RECURRENCE
	138	70 64. DATE OF FIRST RECURRENCE
	139	71 65. TYPE OF FIRST RECURRENCE
	140	66. DATE OF LAST CONTACT OR DEATH
	141	67. VITAL STATUS
	142	68. CANCER STATUS
	143	69. COMPLETED BY
	144	70. CLINICAL REVIEW BY CA COMMITTEE
	145	66. DATE OF LAST CONTACT OR DEATH..:
	146	15 67. VITAL STATUS...................
	147	68. CANCER STATUS..................:
	148	81 69. COMPLETED BY...................
	149	82 70. CLINICAL REVIEW BY CA COMMITTEE
	150	8. PRIMARY PAYER AT DIAGNOSIS.......:
	151	9. FAMILY HISTORY OF PROSTATE CANCER:
	152	10. CLASS OF CASE....................:
	153	11. SYMPTOMS PRESENT AT INITIAL DIAGNOSIS:
	154	LOWER BACK PAIN.................:
	155	TROUBLE URINATING...............:
	156	12. INITIAL METHODS OF DIAGNOSIS:
	157	CLINICAL DX W BONE LESION.......:
	158	CLINICAL DX BY RECTAL EXAM......:
	159	DIGITAL TRANSRECTAL BIOPSY......:
	160	INCIDENTAL FINDING IN TURP FOR BENIGN DISEASE..................:
	161	NEEDLE BIOPSY, NOS..............:
	162	PERINEAL BIOPSY.................:
	163	TRUS GUIDED BIOPSY..............:
	164	13. DIAGNOSTIC EVALUATION:
	165	BONE MARROW ASPIRATION..........:
	166	BONE SCAN.......................:
	167	CT SCAN OF ABDOMEN..............:
	168	CT SCAN OF PELVIS...............:
	169	PELVIC LYMPH NODE DISSECTION....:
	170	ULTRASOUND OF ABDOMEN...........:
	171	14. RESULTS OF MOST RECENT PRE-
	172	TREATMENT PSA TEST...............:
	173	15. DATE OF INITIAL DIAGNOSIS........:
	174	16. PRIMARY SITE (ICD-O-2)...........:
	175	18. BEHAVIOR CODE (ICD-O-2)..........:
	176	20. BIOPSY PROCEDURE.................:
	177	21. GUIDANCE OF BIOPSY TO PRIMARY....:
	178	22. BIOPSY APPROACH FOR PRIMARY......:
	179	23. BIOPSY OF OTHER THAN PRIMARY.....:
	180	24. DIAGNOSTIC CONFIRMATION..........:
	181	GLEASON SCORE...................:
	182	27. SIZE OF TUMOR (mm)...............:
	183	28. REGIONAL NODES EXAMINED..........:
	184	29. REGIONAL NODES POSITIVE..........:
	185	30. AJCC CLINICAL STAGE (cTNM):
	186	31. AJCC PATHOLOGIC STAGE (pTNM):
	187	32. STAGED BY:
	188	33. DATE OF FIRST COURSE TREATMENT...:
	189	34. EXPECTED MGT/WATCHFUL WAITING....:
	190	35. DATE OF NON CA-DIRECTED SURGERY..:
	191	36. NON CANCER-DIRECTED SURGERY......:
	192	37. DATE OF CANCER-DIRECTED SURGERY..:
	193	38. LENGTH OF STAY AFTER SURGERY.....:
	194	39. SURGICAL APPROACH................:
	195	40. TYPE OF CANCER-DIRECTED SURGERY..:
	196	41. SURGICAL MARGINS.................:
	197	42. SCOPE OF LYMPH NODE SURGERY......:
	198	43. TYPE OF LYMPH NODE SURGERY:
	199	44. SURGERY OF OTHER REGIONAL SITE(S), DISTANT SITE(S),
	200	45. NUMBER OF LYMPH NODES REMOVED....:
	201	47. COMPLICATIONS FOLLOWING SURGICAL FIRST COURSE OF TREATMENT:
	202	PERMANENT RECTAL INJURY.........:
	203	URETHRAL STRICTURE..............:
	204	48. POSTOPERATIVE DEATH W/I 30 DAYS..:
	205	49. DATE RADIATION STARTED...........:
	206	50. RADIATION THERAPY................:
	207	51. RADIATION FACILITY...............:
	208	52. INTERSTITIAL RADIATION/BRACHYTHERAPY ADMINISTERED:
	209	OTHER INTERSTITIAL, NOS.........:
	210	53. ROUTE OF INTERSTITIAL RADIATION/
	211	BRACHYTHERAPY ADMINISTERED.......:
	212	54. EXTERNAL RADIATION ADMINISTERED:
	213	DISTANT METASTATIC SITES........:
	214	PROSTATE & PELVIC NODES.........:
	215	PROSTATE & PARA-AORTIC NODES....:
	216	PROSTATE REGION ONLY............:
	217	OTHER EXTERNAL SITES, NOS.......:
	218	55. TYPE OF EXTERNAL RADIATION
	219	56. TOTAL EXTERNAL RAD DOSE (cGy) INCLUDING BOOST:
	220	PELVIC NODES....................:
	221	PARA-AORTIC NODES...............:
	222	57. COMPLICATIONS FOLLOWING RADIATION FIRST COURSE OF TREATMENT:
	223	ACUTE GASTROINTESTINAL..........:
	224	ACUTE GASTROURINARY.............:
	225	PROLONGED HOSPITALIZATION.......:
	226	URETHRAL OR BLADDER.............:
	227	58. DATE OF ORCHIECTOMY.............:
	228	59. DATE EXOGENOUS HT BEGAN.........:
	229	60. HORMONE THERAPY.................:
	230	61. EXOGENOUS HORMONE AGENTS ADMINISTERED:
	231	LUTEINIZING HORMONES............:
	232	PROGESTATIONAL AGENTS...........:
	233	62. DATE CHEMOTHERAPY STARTED........:
	234	64. DATE OF FIRST RECURRENCE.........:
	235	65. TYPE OF FIRST RECURRENCE.........:
	236	66. DATE OF LAST CONTACT OR DEATH....:
	237	67. VITAL STATUS.....................:
	238	68. CANCER STATUS....................:
	239	69. COMPLETED BY.....................:
	240	70. REVIEWED BY CANCER COMMITTEE.....:
	241	ROADS TO FORDS
	242	7 PLACE OF BIRTH.............
	243	9 SPANISH ORIGIN.............//^S X=
	244	Non-Spanish, non-Hispanic
	245	48 AGENT ORANGE EXPOSURE......//^S X=AOE
	246	50 IONIZING RADIATION EXPOSURE//^S X=IRE
	247	52 CHEMICAL EXPOSURE..........
	248	61 ASBESTOS EXPOSURE..........
	249	51 PERSIAN GULF SERVICE.......//^S X=PGS
	250	55 MIDDLE EAST SERVICE........//^S X=MES
	251	56 SOMALIA SERVICE............//^S X=SS
	252	Reporting Hospital..........:
	253	Marital status at Dx........:
	254	Patient address at Dx.......:
	255	Patient address at Dx - Supp:
	256	City/town at Dx.............:
	257	State at Dx.................:
	258	Postal code at Dx...........:
	259	County at Dx................:
	260	Census Tract................:
	261	Following physician.........:
	262	Primary surgeon.............:
	263	Primary payer at Dx.........:
	264	Type of reporting source....:
	265	Class of Case................:
	266	Facility referred from.......:
	267	Facility referred to.........:
	268	Date of First Contact........:
	269	Date Dx......................:
	270	Dx Facility..................:
	271	Histology/Behavior Code......:
	272	AFIP submission..............:
	273	Diagnostic Confirmation......:
	274	Presentation at Cancer Conf..:
	275	Place of birth.............:
	276	Spanish origin.............:
	277	Agent Orange exposure......:
	278	Ionizing radiation exposure:
	279	Chemical exposure..........:
	280	Asbestos exposure..........:
	281	Persian Gulf service.......:
	282	Middle East service........:
	283	Somalia service............:
	284	Usual Occupation...........:
	285	Usual Industry.............:
	286	Tobacco History............:
	287	Alcohol History............:
	288	Family History of Cancer...:
	289	Family Member with Cancer..:
	290	PREVIOUS HISTORY OF CANCER
	291	Previous History of Cancer.....:
	292	1///Unknown if BRM therapy administered
	293	Patient Care Evaluation Studies of Cancer of the Prostate
	294	DATE OF ADMISSION
	295	ACCESSION/SEQUENCE NUMBER.:
	296	CLASS OF CASE.............:
	297	9ZIP CODE..................
	298	BIRTHDATE.................:
	299	18PRIMARY PAYER AT DIAGNOSIS
	300	1DATE OF ADMISSION.........
	301	1.1DATE OF DISCHARGE.........
	302	METHOD OF DIAGNOSIS
	303	#################### #################### ####################
	304	#################### #################### ####################
	305	#################### #################### ####################
	306	#################### #################### ####################
	307	#################### #################### ####################

Note: See TracBrowser for help on using the repository browser.

Context Navigation

source: internationalization/trunk/TranslationSpreadsheets/WV-DIALOG-0247.txt@ 1727

Download in other formats: